Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for ChromaDex Corporation (CDXC : NSDQ)
 
 • Company Description   
ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical and cosmetic markets. ChromaDex's core business strategy is to use the intellectual property harnessed by its expertise in the area of natural products and in the creation of reference materials to the industry as the basis for providing new and alternative, `green`, mass marketable products to its customers. The Company's main priority is to create industry-accepted information, and to provide products and services to every layer of the functional food, pharmaceutical, personal care and dietary supplement markets. The company markets and sells its products in the United States and Canada. It offers its products through distributors in Europe, South America, Korea, India, Japan, Australia, New Zealand, China, Indonesia, Malaysia, Singapore, Thailand, and Mexico.

Number of Employees: 115

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.91 Daily Weekly Monthly
20 Day Moving Average: 412,033 shares
Shares Outstanding: 68.33 (millions)
Market Capitalization: $130.52 (millions)
Beta: 1.79
52 Week High: $10.78
52 Week Low: $1.52
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -4.02% 8.09%
12 Week -26.25% -18.93%
Year To Date -48.93% -42.50%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
10900 Wilshire Blvd. Suite 600
-
Los Angeles,CA 90024
USA
ph: 310-388-6706
fax: 949-419-0294
investorrelations@chromadex.com http://www.chromadex.com
 
 • General Corporate Information   
Officers
Robert Fried - Chief Executive Officer and Director
Frank L. Jaksch - Executive Chairman of the Board and Director
Kevin Farr - Chief Financial Officer
Stephen Block - Director
Jeff Baxter - Director

Peer Information
ChromaDex Corporation (CORR.)
ChromaDex Corporation (RSPI)
ChromaDex Corporation (CGXP)
ChromaDex Corporation (BGEN)
ChromaDex Corporation (GTBP)
ChromaDex Corporation (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 171077407
SIC: 2833
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/02/22
Share - Related Items
Shares Outstanding: 68.33
Most Recent Split Date: 4.00 (0.33:1)
Beta: 1.79
Market Capitalization: $130.52 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.07 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.29 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/02/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 5.04
Price/Cash Flow: -
Price / Sales: 1.86
EPS Growth
vs. Year Ago Period: 8.33%
vs. Previous Quarter: -37.50%
Sales Growth
vs. Year Ago Period: 17.54%
vs. Previous Quarter: -2.82%
ROE
03/31/22 - -81.32
12/31/21 - -70.85
09/30/21 - -80.96
ROA
03/31/22 - -46.38
12/31/21 - -42.87
09/30/21 - -47.76
Current Ratio
03/31/22 - 2.38
12/31/21 - 2.78
09/30/21 - 2.97
Quick Ratio
03/31/22 - 1.56
12/31/21 - 2.00
09/30/21 - 2.26
Operating Margin
03/31/22 - -39.25
12/31/21 - -40.22
09/30/21 - -42.83
Net Margin
03/31/22 - -39.25
12/31/21 - -40.22
09/30/21 - -42.83
Pre-Tax Margin
03/31/22 - -39.25
12/31/21 - -40.22
09/30/21 - -42.83
Book Value
03/31/22 - 0.38
12/31/21 - 0.46
09/30/21 - 0.52
Inventory Turnover
03/31/22 - 2.03
12/31/21 - 2.03
09/30/21 - 2.04
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.03
 

Powered by Zacks Investment Research ©